Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity.
Biffen M, Matsui H, Edwards S, Leishman AJ, Eiho K, Holness E, Satterthwaite G, Doyle I, Wada H, Fraser NJ, Hawkins SL, Aoki M, Tomizawa H, Benjamin AD, Takaku H, McInally T, Murray CM. Biffen M, et al. Among authors: leishman aj. Br J Pharmacol. 2012 May;166(2):573-86. doi: 10.1111/j.1476-5381.2011.01790.x. Br J Pharmacol. 2012. PMID: 22122192 Free PMC article.
Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Koga-Yamakawa E, Dovedi SJ, Murata M, Matsui H, Leishman AJ, Bell J, Ferguson D, Heaton SP, Oki T, Tomizawa H, Bahl A, Takaku H, Wilkinson RW, Harada H. Koga-Yamakawa E, et al. Among authors: leishman aj. Int J Cancer. 2013 Feb 1;132(3):580-90. doi: 10.1002/ijc.27691. Epub 2012 Jul 11. Int J Cancer. 2013. PMID: 22733292 Free article.
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, Goodwin R, Herbst R, Tomai MA, Wilkinson RW. Mullins SR, et al. Among authors: leishman aj. J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8. J Immunother Cancer. 2019. PMID: 31511088 Free PMC article.
Immunology: turning basic research into a therapy.
Leishman AJ, Bundick RV. Leishman AJ, et al. Immunol Lett. 2005 Jun 15;99(1):1-7. doi: 10.1016/j.imlet.2004.12.011. Epub 2005 Jan 12. Immunol Lett. 2005. PMID: 15894103 Review.
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Williams GS, Mistry B, Guillard S, Ulrichsen JC, Sandercock AM, Wang J, González-Muñoz A, Parmentier J, Black C, Soden J, Freeth J, Jovanović J, Leyland R, Al-Lamki RS, Leishman AJ, Rust SJ, Stewart R, Jermutus L, Bradley JR, Bedian V, Valge-Archer V, Minter R, Wilkinson RW. Williams GS, et al. Among authors: leishman aj. Oncotarget. 2016 Oct 18;7(42):68278-68291. doi: 10.18632/oncotarget.11943. Oncotarget. 2016. PMID: 27626702 Free PMC article.
28 results